Drug Profile
Research programme: antibody and small molecule therapeutics - Applied Immunotherapeutics/Feinstein Institute for Medical Research
Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Karolinska Institute; The Feinstein Institute for Medical Research
- Class Anti-inflammatories; Antianaemics; Antibodies; Antihyperglycaemics; Antirheumatics; Small molecules
- Mechanism of Action HMGB1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anaemia; Autoimmune disorders; Diabetes mellitus; Inflammation; Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for research development in Anaemia in Sweden
- 28 Aug 2021 No recent reports of development identified for research development in Anaemia in USA
- 28 Aug 2021 No recent reports of development identified for research development in Autoimmune-disorders in Sweden